• 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, also called Triapine) is a substance that is being studied in the treatment of cancer. (wikipedia.org)
  • The synthesis of new more selective and less toxic compounds led to the attainment of a novel drug (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, ATSC), which is currently involved in phase I and II clinical trials 10-13 . (uninet.edu)
  • 13. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. (nih.gov)
  • Background: 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. (psu.edu)
  • 6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. (nih.gov)
  • 3AP is a potent inhibitor of ribonucleotide reductase, the rate determining enzyme in the supply of deoxynucleotides (DNA building blocks) for DNA synthesis. (wikipedia.org)
  • Among the last ones, it is remarkable the inhibition of ribonucleotide reductases (RNRs), enzymes that transform ribonucleoside diphosphates into deoxyribonucleoside diphospates to give the basic constituents of DNA 9 . (uninet.edu)
  • 1. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. (nih.gov)
  • 3. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. (nih.gov)
  • 7. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies. (nih.gov)
  • 10. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies. (nih.gov)
  • It is a very strong iron chelator and in the body it is likely that the iron chelate is the active species that quenches the active site tyrosyl radical required by ribonucleotide reductase for its enzymatic activity. (wikipedia.org)